CTXR Citius Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 14:45
Why CTXR matters now
Citius Pharmaceuticals, Inc. (CTXR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.58 with +2.62% on the session and $6.4M in market capitalization; recent performance reads 1-month -1.41% and YTD -29.68%.
The latest financial table shown here is Q2 2026, with revenue of $1.7M, net income of $-21.2M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -517.5%.
The latest indexable market news headline is "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.20
P/S
1.09
EV/EBITDA
-0.04
DCF Value
$0.93
FCF Yield
-517.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.4%
Operating Margin
-1041.4%
Net Margin
-823.3%
ROE
-67.4%
ROA
-34.9%
ROIC
-75.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.7M | $-21.2M | $-0.95 |
| Q1 2026 | $3.9M | $-8.2M | $-0.38 |
| Q4 2025 | $0.00 | $-8.0M | $-0.44 |
| FY 2025 | $0.00 | $-37.4M | $-3.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.98
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.